Heme (Ferriprotoporphyrin IX) and plasmodial membrane phospholipids (FPPIX)

Heme and plasmodial membrane phospholipids represent the biochemical targets of the antimalarial drug lumefantrine. During the infection of human erythrocytes, Plasmodium parasites catabolize hemoglobin, which releases free ferriprotoporphyrin IX (heme), a molecule that is highly toxic to the parasite due to its oxidative potential and ability to damage cellular membranes (Source: PubChem, CID 6437387). To prevent cellular damage, the parasite normally sequesters heme into a crystalline, non-toxic form known as hemozoin. Lumefantrine acts by binding to these heme molecules, effectively inhibiting the crystallization process and causing the accumulation of toxic heme-drug complexes within the parasite's food vacuole (Source: DrugBank, DB06708). Additionally, lumefantrine is thought to interact with the phospholipids of the plasmodial membrane, which may impair the function of membrane-associated proteins or disrupt the integrity of the parasite's internal compartments (Source: PubMed, PMID 11516310). This dual mechanism of action is essential for the efficacy of artemisinin-based combination therapies (ACTs), where lumefantrine provides a sustained parasiticidal effect to ensure complete clearance of the infection after the rapid action of artemisinins (Source: WHO Malaria Terminology).

Other names

Ferriprotoporphyrin IXFPPIXHemeParasite membrane lipidsHemozoin precursor

Inhibition of hemozoin formation by binding to ferriprotoporphyrin IX and potential disruption of parasite membrane phospholipid function.